Novel BRCA1/2 mutations in Serbian breast and breast-ovarian cancer patients with hereditary predisposition

Cancer Genetics and Cytogenetics

Volumn 202, Issue 1, 2010, Pages 27-32

  Dobričić, Jelena ^a   Branković Magić, Mirjana ^a   Filipović, Sladana ^b   Radulović, Siniša ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b Clinical Center Ni   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; STEROID RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CASE REPORT; DATA BASE; DNA REPAIR; DNA SEQUENCE; EXON; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; NUCLEOTIDE SEQUENCE; ONSET AGE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; SERBIA; ANAMNESIS; BREAST TUMOR; COMPLICATION; GENETICS; MALE; MOLECULAR GENETICS; MUTATION; OVARY TUMOR; PEDIGREE;

AGE OF ONSET; BASE SEQUENCE; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MEDICAL HISTORY TAKING; MOLECULAR SEQUENCE DATA; MUTATION; OVARIAN NEOPLASMS; PEDIGREE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SERBIA;

EID: 77956146323     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.06.001     Document Type: Article

References (23)

1. Gudmundsdottir K., Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006, 25:5864-5874.
2. Ferla R., Caló V., Cascio S., Rinaldi G., Badalamenti G., Carreca I., et al. Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 2007, 18(Suppl 6). vi, 93-8.
3. Górski B., Jakubowska A., Huzarski T., Byrski T., Gronwald J., Grzybowska E., et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 2004, 110:683-686.
4. Oddoux C., Struewing J.P., Clayton C.M., Neuhausen S., Brody L.C., Kaback M., et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996, 14:188-190.
5. Simard J., Tonin P., Durocher F., Morgan K., Rommens J., Gingras S., et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 1994, 8:392-398.
6. Thorlacius S., Olafsdottir G., Tryggvadottir L., Neuhausen S., Jonasson J.G., Tavtigian S.V., et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996, 13:117-119.
7. Hosey A.M., Górski J.J., Murray M.M., Quinn J.E., Chung W.Y., Stewart G.E., et al. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 2007, 99:1683-1694.
8. Tung N., Wang Y., Collins L.C., Kaplan J., Li H., Gelman R., et al. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res 2010, 12. R12.
9. Lakhani S.R., Jacquemier J., Sloane J.P., Gusterson B.A., Anderson T.J., Vijver M.J., et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998, 90:1138-1145.
10. den Dunnen J.T., Antonarakis S.E. Nomenclature for the description of human sequence variations. Hum Genet 2001, 109:121-124.
11. Jackson S.P., Bartek J. The DNA-damage response in human biology and disease. Nature 2009, 461:1071-1078.
12. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
13. Meza J.E., Brzovic P.S., King M.C., Klevit R.E. Mapping the functional domains of BRCA1. Interaction of the ring finger domains of BRCA1 and BARD1. J Biol Chem 1999, 274:5659-5665.
14. Huen M.S.Y., Sy S.M.H., Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 2010, 11:138-148.
15. Yarden R.I., Brody L.C. BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci U S A 1999, 96:4983-4988.
16. Lim E., Vaillant F., Wu D., Forrest N.C., Pal B., Hart A.H., et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009, 15:907-913.
17. Wooster R., Neuhausen S.L., Mangion J., Quirk Y., Ford D., Collins N., et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994, 265:2088-2090.
18. Tavtigian S.V., Simard J., Rommens J., Couch F., Shattuck-Eidens D., Neuhausen S., et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996, 12:333-337.
19. 2/M checkpoint control. J Biol Chem 1999, 274:32931-32935.
20. Wong A.K.C., Pero R., Ormonde P.A., Tavtigian S.V., Bartel P.L. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 1997, 272:31941-31944.
21. Pellegrini L., Yu D.S., Lo T., Anand S., Lee M., Blundell T.L., et al. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 2002, 420:287-293.
22. Scully R., Livingston D.M. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000, 408:429-432.
23. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002, 108:171-182.